Vor Biopharma (NASDAQ:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 27,624 Shares of Stock

Vor Biopharma Inc. (NASDAQ:VOR) major shareholder Reprogrammed Interchange Llc sold 27,624 shares of the company’s stock in a transaction that occurred on Tuesday, October 7th. The shares were sold at an average price of $33.84, for a total transaction of $934,796.16. Following the completion of the sale, the insider directly owned 1,498,921 shares of the company’s stock, valued at $50,723,486.64. The trade was a 1.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Monday, October 6th, Reprogrammed Interchange Llc sold 70,763 shares of Vor Biopharma stock. The shares were sold at an average price of $37.01, for a total transaction of $2,618,938.63.
• On Friday, October 3rd, Reprogrammed Interchange Llc sold 7,901 shares of Vor Biopharma stock. The shares were sold at an average price of $37.83, for a total transaction of $298,894.83.
• On Thursday, October 2nd, Reprogrammed Interchange Llc sold 32,451 shares of Vor Biopharma stock. The shares were sold at an average price of $39.83, for a total transaction of $1,292,523.33.
• On Wednesday, October 1st, Reprogrammed Interchange Llc sold 1,400 shares of Vor Biopharma stock. The shares were sold at an average price of $39.19, for a total transaction of $54,866.00.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 447,278 shares of Vor Biopharma stock. The shares were sold at an average price of $1.54, for a total transaction of $688,808.12.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 22,363 shares of Vor Biopharma stock. The shares were sold at an average price of $30.80, for a total transaction of $688,780.40.
• On Monday, September 15th, Reprogrammed Interchange Llc sold 20,000 shares of Vor Biopharma stock. The shares were sold at an average price of $32.80, for a total transaction of $656,000.00.
• On Friday, September 12th, Reprogrammed Interchange Llc sold 15,000 shares of Vor Biopharma stock. The shares were sold at an average price of $35.00, for a total transaction of $525,000.00.
• On Thursday, September 11th, Reprogrammed Interchange Llc sold 14,240 shares of Vor Biopharma stock. The shares were sold at an average price of $36.60, for a total transaction of $521,184.00.
• On Monday, September 8th, Reprogrammed Interchange Llc sold 23,221 shares of Vor Biopharma stock. The shares were sold at an average price of $39.80, for a total transaction of $924,195.80.

Vor Biopharma Price Performance

Vor Biopharma stock opened at $33.40 on Thursday. The firm has a market capitalization of $228.79 million, a PE ratio of -0.12 and a beta of 2.07. Vor Biopharma Inc. has a twelve month low of $2.62 and a twelve month high of $65.80. The firm has a 50 day moving average of $38.14.

Vor Biopharma (NASDAQ:VOR) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($43.60) earnings per share for the quarter, missing the consensus estimate of ($11.40) by ($32.20).

Hedge Funds Weigh In On Vor Biopharma

Several large investors have recently modified their holdings of VOR. Money Concepts Capital Corp raised its position in shares of Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock valued at $37,000 after purchasing an additional 26,535 shares during the period. Goldman Sachs Group Inc. increased its position in Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after acquiring an additional 58,247 shares during the period. XTX Topco Ltd bought a new position in Vor Biopharma during the second quarter worth about $66,000. OMERS ADMINISTRATION Corp bought a new position in Vor Biopharma during the first quarter worth about $100,000. Finally, Jane Street Group LLC bought a new position in Vor Biopharma during the first quarter worth about $140,000. 97.29% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on VOR. Stifel Nicolaus upgraded shares of Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 target price for the company in a report on Wednesday, September 24th. Wedbush reiterated an “outperform” rating on shares of Vor Biopharma in a research note on Thursday, June 26th. Zacks Research upgraded shares of Vor Biopharma from a “strong sell” rating to a “hold” rating in a research note on Wednesday, September 10th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Vor Biopharma in a research note on Thursday, August 14th. Finally, Wall Street Zen cut shares of Vor Biopharma to a “strong sell” rating in a research note on Saturday, June 28th. Five analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $113.83.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.